AZTA
Azenta, Inc.
AZTA lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AZTA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Stable | |
| Strong |
AZTA's revenue and balance sheet are currently healthy, and its cash flow is stable, but its profitability is weak.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AZTA PE Valuation
AZTA has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AZTA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
AZTA has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AZTA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.55 | — |
| Q3 2026 | -$3.62 | -$2.41 |
AZTA lost $3.62 per share over the past year, a bigger loss than the year before.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over AZTA in the latest year-over-year earnings comparison.
AZTA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $167.1M | +5% |
| Q2 2026 | $161.2M | +12% |
| Q1 2026 | $144.8M | +1% |
| Q4 2025 | $148.6M | +0.8% |
AZTA's revenue has grown year over year every quarter since late 2025: $167M last quarter, up 5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2.6% | -2.1 points |
| Q1 2026 | -115% | -103 points |
| Q4 2025 | -4.9% | +2.8 points |
| Q3 2025 | 1.2% | N/A |
| Q2 2025 | -0.5% | N/A |
| Q1 2025 | -11% | N/A |
| Q4 2024 | -7.7% | N/A |
AZTA has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AZTA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AZTA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5.2M | -135% |
| Q1 2026 | $6.1M | -13% |
| Q4 2025 | $14.7M | -34% |
HIMS has the edge over AZTA in the latest year-over-year cash flow comparison.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AZTA in the latest year-over-year cash flow comparison.
AZTA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -777K shares |
| 1 year | -1.2% | -537K shares |
AZTA has 45M diluted shares, down 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AZTA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AZTA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -9.7x | Net Cash |
| Q3 2025 | -8.0x | Net Cash |
| Q2 2025 | -9.0x | Net Cash |
| Q1 2025 | -10.6x | Net Cash |
AZTA has the edge over HIMS on leverage, with a lower net debt burden relative to earnings.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AZTA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.0 | Neutral |
| Stochastic | 64.2 | Neutral |
AZTA's weekly RSI is 69 (neutral) and its Stochastic is 64 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AZTA PE vs Healthcare Sector
| Metric | AZTA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AZTA has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AZTA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $37.9 | 16% above |
| 20 week MA | $33.4 | 31% above |
| 50 week MA | $29.8 | 47% above |
| 100 week MA | $32.5 | 35% above |
| 200 week MA | $42.0 | 4.5% above |
AZTA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AZTA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $42.1 | $74.6 | +77% |
| 2021 | $74.6 | $101.0 | +35% |
| 2022 | $101.0 | $58.5 | -42% |
| 2023 | $58.5 | $65.1 | +11% |
| 2024 | $65.1 | $51.3 | -21% |
| 2025 | $51.3 | $34.8 | -32% |
| 2026 YTD | $34.8 | $43.9 | +26% |
AZTA has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.